Calithera’s Telaglenastat Doubles PFS In Proof-Of-Concept Study

 
• By Alexandra Shimmings

The US biotech’s product becomes the first glutaminase inhibitor to show proof of concept. Calithera now awaits data from a larger registrational study next year in renal cell carcinoma.

Human kidney on scientific background. 3d illustration
• Source: Shutterstock

More from Clinical Trials

More from R&D